Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

Unverricht-Lundborg Disease Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00368251
• Other study ID #: N01236
• Secondary ID: 2006-001536-46
• Status: Completed
• Phase: Phase 3
• Start date: November 2006
• Est. completion date: January 2008

Study information

• Verified date: May 2023
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: January 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Subjects with diagnosed Unverricht-Lundborg disease (ULD) ascertained by appropriate genetic testing for a homozygous or compound heterozygous mutation in the CSTB gene- Subjects with moderate to severe myoclonus documented by an Action Myoclonussum score of = 30 (evaluation by investigator)-Subjects currently being or having been treated with clonazepam up to the maximum recommended daily dose of 20 mg or up to their individual optimal dose as assessed by the investigator- Subjects currently being or having been treated with valproate up to the maximum recommended daily dose 60 mg/kg or serum levels of 100 mcg/ml or up to their individual optimal dose as specified by the investigator- Male/female subjects from 16 years onwards. Subjects under 18 years may only be included where legally permitted and ethically accepted

Exclusion Criteria:

• Subjects currently on felbamate or having been on felbamate within less than 18 months prior to Visit 1- Subjects currently treated with phenytoin or having been on phenytoin in the last month prior to Visit 1- Subjects currently on vigabatrine. Subjects having been on vigabatrine if no visual fields examination report available including standard static (Humphrey or Octopus) or cinetic perimetry (Goldman)- Subject taking any drug with possible central nervous system (CNS) effects- Subjects taking any drug that may significantly influence the metabolism of BRV (CYP2C or CYP3A potent inducers/inhibitors)- Known clinically significant acute or chronic illness or illness which may impair reliable participation in the trial, necessitate the use of medication not allowed by protocol or represent a safety risk in the Investigator's opinion- Subjects with history of severe adverse hematological reaction to any drug- Impaired hepatic function: ALAT/SGPT, ASAT/SGOT, alkaline phosphatase, GGT value of more than three times the upper limit of the reference range- History of suicide attempt during the last 5 years- Subject with suicidal ideations within the last year or at risk of suicide attempt unless cleared by written confirmation from a psychiatrist and approved by the UCB physician- Ongoing psychiatric disorder other than mild controlled disorder

Related Conditions & MeSH terms

• Unverricht-Lundborg Disease
• Unverricht-Lundborg Syndrome

Intervention

Other:
• Placebo
Pharmaceutical Form: Tablet Concentration: 2.5 mg, 25 mg and 50 mg Route of Administration: Oral use

Drug:
• BRV 2.5 mg
Pharmaceutical Form: Tablet Concentration: 2.5 mg Route of Administration: Oral use
• BRV 25 mg
Pharmaceutical Form: Tablet Concentration: 25 mg Route of Administration: Oral use
• BRV 50 mg
Pharmaceutical Form: Tablet Concentration: 50 mg Route of Administration: Oral use

Locations

Country	Name	City	State
Canada	150	Montreal	Quebec
Canada	152	Quebec
Canada	151	Vancouver	British Columbia
Finland	100	Helsinki
France	122	Bron
France	121	Lille
France	120	Paris
Israel	170	Tel Aviv
Russian Federation	141	Moscow
Russian Federation	142	Saint Petersburg
Russian Federation	143	Samara
Serbia	161	Belgrade
Serbia	162	Belgrade
Tunisia	180	La Manouba
United States	131	Charlottesville	Virginia
United States	133	Gainesville	Florida
United States	132	New York	New York
United States	135	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
UCB Pharma

Countries where clinical trial is conducted

United States,  Canada,  Finland,  France,  Israel,  Russian Federation,  Serbia,  Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)	The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit.	From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Secondary	Percent Change From Baseline to the End of Treatment Period on the Functional Disability Score (Unified Myoclonus Rating Scale (UMRS) Section 5)	The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit.	Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Secondary	Percent Change From Baseline to the End of Treatment Period on the Stimulus Sensitivity Score (Unified Myoclonus Rating Scale (UMRS) Section 3)	The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit.	Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Secondary	Percent Change From Baseline to the End of Treatment Period on the Myoclonus Patient Questionnaire (Unified Myoclonus Rating Scale (UMRS) Section 1)	The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit.	Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
Secondary	Global Evaluation Score (Investigator) at the End of Treatment Period	The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement).	End of Treatment Period (Week 14 or Early Discontinuation Visit)

External Links

•   FDA Safety Alerts and Recalls
•   Product Information